Table 2 Hazard ratios (HRs) and 95 % confidence intervals (CIs) for different locations of fractures in the time-dependent model
Location | Crude HR (95 % CI) | p-value | Adjusted HR (95 % CI) | p-value | ||
|---|---|---|---|---|---|---|
Overall | ||||||
Tamoxifen use (yes vs. no) | 0.52 | (0.45-0.61) | <0.0001 | 0.59 | (0.51-0.69) | <0.00001 |
Increased dose of tamoxifen, per 100 DDD | 0.98 | (0.97-0.99) | 0.0003 | 0.98 | (0.97-0.99) | 0.0002 |
Increased duration of tamoxifen use, per 100 days | 0.98 | (0.97-0.99) | 0.0004 | 0.98 | (0.97-0.99) | 0.0002 |
Hip fracture | ||||||
Tamoxifen use (yes vs. no) | 0.48 | (0.39-0.57) | <0.0001 | 0.55 | (0.45-0.67) | <0.0001 |
Increased dose of tamoxifen, per 100 DDD | 0.97 | (0.96-0.99) | 0.0003 | 0.97 | (0.96-0.99) | 0.0005 |
Increased duration of tamoxifen use, per 100 days | 0.98 | (0.96-0.99) | 0.001 | 0.97 | (0.96-0.99) | 0.0004 |
Vertebral fracture | ||||||
Tamoxifen use (yes vs. no) | 0.59 | (0.46-0.75) | <0.0001 | 0.64 | (0.50-0.82) | 0.0003 |
Increased dose of tamoxifen, per 100 DDD | 0.98 | (0.97-1.00) | 0.15 | 0.98 | (0.97-1.00) | 0.06 |
Increased duration of tamoxifen use, per 100 days | 0.98 | (0.97-1.00) | 0.09 | 0.98 | (0.97-1.00) | 0.06 |
Wrist fracture | ||||||
Tamoxifen use (yes vs. no) | 0.86 | (0.43-1.71) | 0.66 | 0.84 | (0.42-1.68) | 0.62 |
Increases dose of tamoxifen, per 100 DDD | 1.01 | (0.96-1.06) | 0.83 | 1.01 | (0.96-1.06) | 0.76 |
Increased duration of tamoxifen use, per 100 days | 1.01 | (0.96-1.05) | 0.83 | 1.01 | (0.96-1.05) | 0.86 |